Health and Healthcare
Stem Cell Stocks Take Off (ASTM, GERN, OPXA, STEM)
Published:
Last Updated:
Tickerspy’s Stem Cell Stock Index (*RSXTM) took off today, rising nearly 13%. The movement followed a release from the National Institutes of Health (NIH) announcing that 13 embryonic stem cell lines were approved for funding.
Opexa Therapeutics Inc (NASDAQ: OPXA) led the rise in stem cell stocks, surging over 40%. The company seeks to develop treatments to major illnesses, such as multiple sclerosis and diabetes, through stem cell research. The company’s stock has risen 2837% off its lows for the year.
StemCells Inc (NASDAQ: STEM) rose over 30% to a high of $1.45. The company engages in research aimed at developing treatment for organ damage using stem cells. The company’s stock is up over 1544% off its low for the year.
Garrett W. McIntyre
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.